Vinge has advised SmartCella Holding AB in connection with its fund raising of EUR 50 million. The capital was invested by, among others, AstraZeneca, the Fourth Swedish National Pension Fund, AMF Pension, SEB-Stiftelsen, Handelsbanken Fonder and RoosGruppen AB. SmartCella is a world-leading biotechnology company pioneering the future of targeted therapies by combining first-in-class delivery platforms with cutting-edge cell and gene therapies.
Vinge’s team consisted of Jesper Ottergren, Sofie Bjärtun, Erik Sjöman, Stojan Arnerstål, Martin Madsen Svanberg, Annie Fällström, Joel Magnusson, Johan Severinsson and Nathalie Wikman.
